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This article outlines a pathway to develop the business case for One Health. It describes the 
origin and development of One Health and then identifies five potential areas where One 
Health can add value and reduce costs. These are: (1) sharing health resources between 
the medical and veterinary sectors; (2) controlling zoonoses in animal reservoirs; (3) early 
detection and response to emerging diseases; (4) prevention of pandemics; and (5) generating 
insights and adding value to health research and development. Examples are given for each 
category along with preliminary estimates of the potential savings from adopting the One 
Health approach. The literature reviewed suggests that one dollar invested in One Health can 
generate five dollars worth of benefits and a global investment of US$25 billion over 10 years 
could generate benefits worth at least US$125bn. Conservation implications: the time has 
come to make the bigger case for massive investment in One Health in order to transform the 
management of neglected and emerging zoonoses and to save the lives of millions of people 
and hundreds of millions of animals whose production supports and nourishes billions of 
impoverished people per annum.
Introduction
This article is based on an invited keynote presentation given at the Southern African Centre for 
Infectious Disease Surveillance (SACIDS) One Health (OH) conference held in Arusha, Tanzania 
in April 2013 (Grace 2013). It draws on the experiences of the International Livestock Research 
Institute (ILRI) that were gathered through a number of OH and Ecohealth (EH) projects over the 
last decade and incorporates findings from a literature review. 
OH is a broad movement that recognises the fact that human, animal and ecosystem health are 
interdependent and that multidisciplinary collaborations are often necessary in order to attain 
optimum health solutions. The article was motivated by a growing consensus that although OH 
is well understood and appreciated it has yet to gain large-scale traction in the medical and donor 
communities. 
As of 2013, OH is endorsed by global standard makers, namely, the World Organisation for Animal 
Health (OIE), the World Health Organization (WHO) and the Food and Agriculture Organization 
of the United Nations (FAO), as well as being supported by the World Bank. The last decade has 
seen a large number of conferences and a series of international inter-ministerial meetings with 
a focus on avian and pandemic influenza. There are currently around 20 universities offering 
OH graduate degree courses, including institutes in America, Africa, Europe and Asia. The OH 
Initiative acts as a clearinghouse for information on OH (http://www.onehealthinitiative.com), 
the One Health Global Network operates a web-portal (http://www.onehealthglobal.net/) to 
facilitate communication and the One Health Commission also shares information (https://
www.onehealthcommission.org/). The EcoHealth Journal publishes on EH and articles on both 
OH and EH have appeared in other major epidemiology and infection journals. In addition, 2012 
saw a major new publication on EH (Charron 2012), updating the classic by Lebel (2003).
However, despite this large and growing body of evidence supporting the usefulness of OH, the 
great majority of medical education, clinical practice, ancillary services, development programmes 
and research continue to operate within disciplinary boundaries. This lack of uptake of OH was 
attributed initially to there being insufficient evidence to convince practitioners and decision 
makers. However, notwithstanding the growing evidence for OH, the organisation of health by 
sectors still persists to a large extent. 
At least partly in response, attention has turned to the economic justification of OH, with an 
important article by the World Bank setting out the potential savings from investing in OH in 
order to prevent pandemics (World Bank 2012). Yet others argue that promotion of OH requires 
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an understanding of how major shifts in health policy and 
practice occur, as well as how the ability to influence opinion 
shifts. Many models exist for both understanding and 
influencing policy change and most of these involve, either 
implicitly or explicitly, a ‘theory of change’. These models 
recognise that evidence is only one part of policy influence 
and that positive influence of policy is highly dependent on 
context (Jones 2011).  
This article discusses the process of building a compelling 
business case for OH in the context of a theory of change for 
adoption thereof. We first discuss various definitions of OH. 
Next, we present a ‘Big Five’ framework for categorising 
OH problems and related interventions. We then provide 
estimates from the literature on the costs of the OH problem 
as well as the likely costs and benefits of OH interventions, 
drawing on a small number of key articles and reports. 
Finally, we provide recommendations for building a 
convincing business case for One Health.
Background and definitions for One 
Health
That human, animal and environmental health is related 
has been recognised throughout the historical development 
of medicine on all continents (Zinsstag et al. 2011). In most 
indigenous and historical medical systems, animal and 
human diseases are conceptualised as having similar causes, 
manifestations and treatments. But as medicine developed 
into a profession, a separation grew between those who 
treated humans and those who treated animals, with 
human doctors given higher status. (That being said, entry 
to veterinary schools in several countries in recent decades 
has been more competitive than entry to medical schools.) In 
the 19th century, European medicine became the dominant 
paradigm and entrenched the largely sectoral approach 
wherein human and animal health was separate disciplines 
and there were only weak connections between ecology and 
health. 
The 20th century saw three major movements, all of which 
contributed largely to current thinking on OH. The first 
was the concept of ‘One Medicine’ which arose out of the 
work of Calvin Schwabe with the Dinka in Sudan (Zinsstag 
et al. 2011). The second movement was ‘Ecosystem Health’ 
or ‘Ecohealth’. This adapted thinking from ecology and 
environmental management to the improvement of human 
health and wellbeing. Important early work on mercury 
contamination in the Amazon basin was supported by the 
Canadian International Development Research Centre, 
which has continued to support research and programmes 
and to develop the approach (Charron 2012). The third 
movement, which took the title of OH, arose because of 
increasing concern of disease emergence at the interface 
between animals, humans and ecosystems (Nabarro 2012). 
This was triggered by a series of disease emergences of global 
importance in the 1990s, including severe acute respiratory 
syndrome (SARS), avian influenza and West Nile virus and 
had strong participation from veterinary and, to a lesser 
extent, human public health.
One Health can be defined as the collaborative effort of 
multiple disciplines to attain optimal health for people, 
animals, and our environment. Ecohealth has been defined 
as systemic, participatory approaches to understanding 
and promoting both health and well-being in the context of 
social and ecological interactions. Both definitions emphasise 
multidisciplinarity and the importance of agriculture and 
ecosystem-based interventions in order to attain health 
goals. The first decade of the 21st century saw an increasing 
convergence of One Health and Ecohealth, leading to the 
development of a broader discipline which incorporates 
infectious and non-infectious disease, epidemiological 
and ecological methods and both disease control and 
development (Zinsstag 2011). 
The boundaries of OH and EH are fuzzy, with interpretations 
differing between groups. For example, the Stone Mountain 
Working Group felt that OH initiatives should address 
human, animal and environmental health simultaneously. 
On the other hand, the EcoHealth Journal (http://www.
Ecohealth.net) publishes not only on zoonoses but also on 
diseases that affect only wildlife (such as bat white-nose 
syndrome). The disease theme of the Consultative Group 
on International Agricultural Research (CGIAR) Research 
Program on Agriculture for Nutrition and Health focuses 
on food-borne diseases and zoonoses but also goes beyond 
zoonoses and occupational hazards to consider such things 
as obesity and anthroponotic but agriculture-related diseases 
as being OH issues (e.g. malaria, which is linked to irrigation 
but is not a zoonosis). 
This article considers as OH both those interventions and 
actions which address diseases that are either actually or 
potentially common to both humans and animals. This 
includes toxicosis due to aflatoxins, heavy metals or other 
injurious substances; resistance to antibiotics, parasiticides or 
other drugs used to treat both humans and animals; classical 
zoonoses such as brucellosis and tuberculosis; and emerging 
diseases such as avian influenza which are either zoonotic or 
potentially zoonotic. 
Framework for categorising One 
Health problems and interventions
Several reviews suggest areas where OH is most likely to 
make a difference (Rushton et al. 2012; World Bank 2012). This 
article identifies a ‘Big Five’ of key areas. For each, the review 
provides a brief description of the area for collaboration, 
cites examples and calculates estimates on costs averted and 
benefits obtained by an OH approach.
Key Areas
Joining up health resources: Sharing health resources 
between sectors
Sharing health resources across human and veterinary health 
sectors would appear to be an easy win. This is especially the 
case for laboratory facilities as the majority of pathogens and 
chemical hazards are common to both humans and animals. 
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Joint laboratory facilities are particularly important in 
developing countries where scarcity of human and financial 
resources challenge the sustained operation of laboratory 
resources. A second area is shared education resources; much 
of the pre-clinical curriculum is common to both human and 
veterinary medicine and there are similar overlaps in many 
paraveterinary and paramedical curricula. Disciplines which 
work at a scale much higher than the individual patient (e.g. 
epidemiology) or much lower (e.g. molecular biology) use 
essentially the same methods for both humans and animals 
and can easily combine forces. There are already some 
courses which target both veterinarians and medical doctors, 
for example joint Masters degrees and the integrated courses 
delivered by the South African Field Epidemiology and 
Laboratory Training Programme (SAFELTP). Surveillance is 
a third area where there are obvious advantages to systems 
which are at least joined up and possibly integrated. Several 
of the most important surveillance systems are ‘One Health’; 
these include ProMED (http://www.promedmail.org), 
HealthMap (http://healthmap.org/en/) and the Global 
Early Warning System (GLEWS, http://www.glews.net). 
A fourth possible area for joining forces is disease control, 
especially in remote, livestock-keeping communities. 
Linking livestock vaccination with vaccination of children 
has been piloted in Chad in communities where the majority 
of livestock, but no children, were vaccinated (Schelling et al. 
2007).
Estimating the benefits of collaboration across medical 
and veterinary services is challenging. The operation of a 
joint laboratory in Winnipeg is estimated to have reduced 
overall costs by 26% (World Bank 2012). The World Bank 
(2012) estimates a 10.0% – 27.5% saving across a range of 
joint services for avian influenza control. The campaign in 
Chad suggested that combining both human and livestock 
vaccination reduced overall costs by 15% (Schelling et al. 
2007). We assume that both of these are on an annual basis.
Human health expenditure in developing countries was 
estimated at US$521 billion in 2012 (IHME 2012). Estimations 
for veterinary health expenditure are less solid, but combining 
data from a number of studies suggests an expenditure 
of US$1bn – US$2bn on public animal health services in 
developing countries (Bonnet et al. 2011; Gallacher 2007; OIE 
2009). Based on the studies cited above, it can be assumed 
that joint operations can save around 10% of the combined 
medical and veterinary budget devoted to those functions 
which are amenable to sharing. Best available evidence 
suggests that laboratories, education and management of 
zoonoses are services which can be shared and that these 
constitute 5% of the human health budget and 40% of the 
veterinary health budget (Eurostat 2012). This implies that the 
total savings of joined-up services could be US$2.68bn per year. 
Given estimates of the cost of collaboration, net savings of 
around US$3bn imply gross savings of around US$4bn per 
year.
Controlling zoonoses in animal reservoirs
Historically, most major zoonoses that have been controlled 
successfully have concentrated on the animal reservoir. This 
includes diseases such as brucellosis, tuberculosis, rabies, 
salmonellosis, cysticercosis, trichinellosis and others which 
have been controlled successfully in many countries. 
A large number of economic analyses have been conducted 
in order to compare the costs and benefits of control and/or 
localised elimination of zoonoses. Table 1 summarises some 
representative studies. Economic assessments conducted 
after a control campaign is finished give results comparable to 
ex ante assessments, which suggests that ex ante assessments 
are credible. (However, this may be less true when animal 
health services are weak.) Whilst a wide range of benefit-to-
cost ratios are reported, all the literature reviewed showed 
a positive ratio. The median ratio of benefits to costs was 
around four to one with human health benefits at least equal 
to animal health benefits and often greater.
This approximate, but relatively robust, estimate allows an 
assessment of the costs and benefits of controlling zoonoses 
in developing countries. A recent study estimates that 
around one in seven (14%) livestock in developing countries 
TABLE 1: A selection of studies showing the costs and benefits of control of zoonoses.
Disease Perspective Country Costs considered Benefit-to cost-ratio Reference
Brucellosis Ex ante Nigeria Livestock only 3.2 Cited in McDermott, Grace and Zinsstag (2013)
Ex ante Mongolia Human health and 
livestock
3.2
Ex post Czech Republic Livestock only 7.1
Ex post England & Wales Human health, 
livestock and trade
2.2
Ex post England & Wales Livestock only 1.1
Ex ante Cyprus Not specified 6.5–21.7
Schistosomiasis - - - 6.0 Grey, Williams, Li and McManus (2008)
Echinococcosis Ex ante Tibet Human health and
livestock
3.0 Budke et al. (2005)
Rabies Ex post USA Human health and 
animal tests
3.4–13.1 Shwiff, Kirkpatrick and Sterner (2008)
Bovine tuberculosis Ex ante UK - 1.71 DEFRA (2011)
Salmonellosis Ex post Finland Human health 19.8 for eggs and 
5.4 for meat
Maijala and Peltola (2002)
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each year are currently or recently infected with one or more 
zoonoses and that each infection reduces their productivity 
by around 10% (Grace 2013). According to the FAO, the 
value of livestock production in developing countries was 
US$639bn per year at the time of their study (FAOSTAT, 
2012), suggesting that the productivity losses related to 
zoonoses is around US$9.26bn per year (assuming that 
current losses are 1.4% and that, without these, production 
would be US$648bn). 
In addition to morbidity, mortality is an important cause of 
loss for livestock. Numerous studies on developing country 
livestock indicate that annual mortality is high. Otte and 
Chilonda (2002) provide the most thorough review (although 
only covering Africa) and this implies a mortality rate of 21% 
weighted by age and species. Assuming that half of livestock 
mortality is because of disease and that half the disease is 
a result of zoonoses (World Bank 2011), then developing 
countries currently lose approximately 68 million tropical 
livestock units (TLU) because of zoonoses (this represents 
25% livestock mortality as a result of zoonoses, namely, 50% 
of 50% of disease-related livestock mortality). To extrapolate, 
assuming that the value of a TLU is US$366, this costs 
developing countries US$25bn per year. On the other hand, 
official reports of the OIE suggest that only around 400 000 
livestock units are lost each year in developing countries – a 
mortality rate of 0.03% (World Bank 2011). This implausibly 
low estimate is an artefact of under-reporting and under-
estimation of losses by between two and three orders of 
magnitude (Grace et al. 2012).
The human health costs of zoonoses are typically equal to 
or greater than the livestock sector losses, a trend which is 
becoming more pronounced with time (World Bank 2012). 
The aforementioned study suggested 2.2 million human 
deaths and 2.4 billion human illnesses a year from zoonoses 
(Grace et al. 2012). Using standard and conservative costs of 
human illness, we may assume losses of at least US$50 billion 
in 2013.
This implies that the annual costs of zoonoses may be US$9bn 
in lost productivity, US$25bn in livestock mortality and 
US$50bn from human health – rounded up to US$85bn in 
all per year. Based on the studies cited in Table 1, the costs 
of control are typically one fourth the benefits and a control 
programme may extend for five to 10 years, so the US$85bn in 
annual losses could be averted by a expenditure of US$21bn 
over this period. (Please note that, for simplicity, we do not 
consider discounting in this or other estimates).
Early outbreak detection
In the case of highly contagious diseases, rapid response is 
key to reducing the cost of disease outbreaks. It is difficult to 
estimate the costs of a counterfactual, that is, the costs that 
would have been incurred had response to outbreaks been 
more timely. However, an approximate quantification of the 
savings obtainable by early and efficient management can be 
obtained by comparing the costs of epidemics caused by the 
same disease in different contexts. For example, control of 
the bovine spongiform encephalitis (BSE) outbreak in Britain 
is considered widely to have been suboptimal because 
of a range of factors (including the novelty of the disease; 
lack of understanding of impacts; over-estimation of the 
effectiveness of control; and the wide establishment of the 
disease). On the other hand, when the disease was introduced 
to other countries, response was more rapid and effective. 
Canada can then act as a counterfactual for the UK and, by 
comparing the costs of the outbreaks in the two countries, we 
can estimate that if control had been as timely and effective 
in the UK as in Canada, 88% of the costs could have been 
averted (Table 2).
Contexts that affect the timeliness of control include: 
whether the disease is a surprise or anticipated; whether 
there is effective surveillance in place or not; and whether 
public services are well funded and well functioning or 
have suboptimal performance. By comparing effectively-
controlled epidemics with poorly-controlled epidemics we 
estimate that well-functioning surveillance systems and 
timely responses may reduce the cost of outbreaks by 95%.
The World Bank estimates that outbreaks have cost on 
average US$6.7bn from 1997–2009 (World Bank 2011). They 
estimate that a US$3.4bn investment in animal health systems 
per annum would support these systems so that they could 
function effectively and efficiently, enabling them to avert 
the losses incurred through delayed or inadequate response. 
A 95% reduction in costs amounts to US$6bn saved per year.
Pandemic prevention 
In addition to the ongoing losses from disease outbreaks, 
which have become the ‘new normal’, there is considerable 
concern over the possibility of a civilisation-altering 
pandemic or plague. These have occurred regularly but 
infrequently throughout history and pre-history, with the 
most recent example being the HIV pandemic. In a landmark 
study, the World Bank considers the possible impacts and 
costs of averting high impact but low probability pandemics 
(Burns, Van der Mensbrugghe & Timmer 2008). We draw 
attention to their key message: 
TABLE 2: Comparing worst case and better case disease surveillance and response incidents.
Outbreak Worse case (US$) Better case (US$) Potential loss averted Context leading to better or worse control
Bovine spongiform encephalitis (BSE) UK 1994: 13 billion Canada 2004: 1.5 billion 88% Known, surveillance in place
Foot and mouth disease (FMD) UK 2001: 30 billion UK 1967: 0.5 billion 98% Lower preparedness, easier spread
Highly pathogenic avian influenza (HPAI) Asia 2004: 20 billion Europe 2005: 0.5 billion 98% Higher preparedness, better systems
Note: Source of data originates from the literature review.
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A severe pandemic costing US$3 trillion may occur, on average, 
once in a hundred years. If the investments in One Health systems 
are made and such a pandemic is prevented, the global expected 
benefits are US$30 billion per year. Every year, an investment 
of US$3.4 billion would produce an expected benefit of US$30 
billion for the international community. (Burns et al. 2008)
This expenditure of US$3.4bn on strengthening veterinary 
services would hence deliver two streams of benefits: averting 
major pandemics with an expected benefit of US$30bn and 
improving the timeliness of response to outbreaks with an 
annual expected benefit of US$6bn a year.
Adding value to health research and development
OH and EH lead to better research and disease control 
programmes as well as ecosystems better able to provide 
health as a regulatory service. Evidence for the value of 
OH and EH has been presented at major conferences. The 
most recent include: Addis (2011), Arusha (2013), Bangkok 
(2013), Davos (2012), Johannesburg (2011), Kunming (2012), 
London (2010) and Melbourne (2011). Important meetings 
have also been held where global health leaders endorsed 
the approach: these include gatherings in New York (2004), 
Winnipeg (2009), Bellagio (2010), London (2009), and Stone 
Mountain (2010). A recent review identified 41 major OH 
initiatives (Rockefeller Foundation 2011), another review 
showcased 31 OH projects (VSF 2010) and a recent book sets 
out EH theory and practice (Charron 2012). 
Whilst a large and growing body of evidence supports the 
hypothesis that adopting both OH and EH improves the 
effectiveness and efficiency of health research and delivery, 
the costs and benefits of adopting OH and EH as an approach 
to research and development are difficult to quantify. It 
is generally accepted that approaches which are highly 
participatory and multidisciplinary may have additional 
costs. On the other hand, participatory approaches can 
decrease some costs and increase sustainability. We consider 
this to be an important area for future research, but are 
unable to provide a monetary estimate.
Discussion
We reviewed the literature in order to develop a framework 
for assessing the benefits of One Health approaches and 
interventions and to summarise information on the values 
thereof. There is an enormous lack of information on the 
burden of zoonoses and much of the evidence that exists is not 
readily available; hence, the estimates in this review should 
not be considered as definitive, but rather as examples of how 
important benefits from OH and EH could be quantified. With 
this caveat, this preliminary review (presented at SACIDS 
2013 [Grace 2013]) has developed initial estimates of the 
possible costs of zoonoses, the investments needed to control 
them and the benefits derived therefrom. Dollar estimates 
are summarised in Table 3: a US$25bn annual investment 
over 10 years would generate annual benefits worth at least 
US$125bn (excluding discounting). Additional benefits 
include saved DALYs (Disability Adjusted Life Years) which 
reflect the disutility of illness, as well as conserved ecosystem 
health regulation through reduction of zoonoses spill-over to 
wildlife.
Developing a comprehensive and credible ex ante assessment 
of the business case for OH and EH requires investment. A 
first step is to develop and evaluate metrics that capture the 
impact of zoonoses and emerging disease on human health, 
the livestock sector, the broader economy and ecosystem 
health regulation. Given the deficiencies of current official 
reporting systems, estimates of disease prevalence and 
impact are best obtained by literature review and ‘ground-
truthing’ studies. However, long-term solutions need to 
involve the upgrading of reporting systems to a standard 
that ensures quality, transparency and reliability. This will 
require an appropriate incentive system to be in place in 
order to elicit such institutional changes amongst the key 
stakeholders and actors involved. Appropriate policies can 
help to institutionalise these processes and functions at 
different levels of the reporting system hierarchy.
The business case also needs to consider the options for 
controlling disease and their likely efficiency, effectiveness 
and acceptability. Developing a detailed business case 
covering the economic case, options, risks and priorities for 
One Health investments would require a multidisciplinary 
team with skills in epidemiology, economics and an 
understanding of developing country livestock sectors. We 
estimate that a five- to 10-person team of experts, supported 
by research assistants and information technology, could 
build the business case in one year, whilst 30 people would 
take just months. We believe that a credible body of evidence 
with regard to the costs, benefits and feasibility of control 
of zoonoses would stimulate investments by donors and 
national governments, as well as by the non-profit and 
private sector.
TABLE 3: Preliminary estimate of costs and benefits of One Health investments over a 10-year period with benefits and costs per year.
One Health investment area Annual benefit (US$) Annual cost (US$) Confidence
Sharing resources 4 billion 1 billion ++
Controlling zoonoses 85 billion 21 billion +++
Ensuring timely response 6 billion 
3.4 billion
++
Averting pandemics 30 billion +
Improving research and development - - +++
Bottom line 125 billion 25 billion ++
Note: This table summarises the estimates provided in this article.
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Conclusion
Emerging and neglected zoonoses have often been managed 
sectorally, but recent decades have shown, case after case, the 
benefits of One Health management. The growing body of 
evidence suggests the time has come to make the bigger case 
for massive investment in One Health in order to transform 
the management of neglected and emerging zoonoses and to 
save the lives of millions of people and hundreds of millions 
of animals whose production supports and nourishes billions 
of impoverished people per annum. 
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